Special and award session
| KDA outstanding citizenship and leadership award lecture LIVE Channel A | 16:10~16:30 / Thursday 7 October Chairman:Chang Beom Lee |
|
|---|---|---|
| Evidence indicating the merits of strict glycemic control especially in early stage of diabetes to decrease the development of microvascular complication and progression of diabetes have been emerging. In addition, some of anti-diabetic drugs showed robust evidence for reducing the risk of CVD and kidney dysfunction, and American and European guidelines recommend use of these medications independent of A1C in type 2 diabetic patients at risk of developing CVD. This session will provide latest understandings of new emerging concepts for near-normal glycemic control including harm, benefit and therapeutic approach. | ||
|
AL1Sharing the experiences of annual service at free clinic in the backcountry for twenty years | |
| Presidential lecture 1 LIVE Channel A | 19:30~20:00 / Thursday 7 October Chairman:Juliana Chan, Kyu Chang Won |
|
|---|---|---|
| Evidence indicating the merits of strict glycemic control especially in early stage of diabetes to decrease the development of microvascular complication and progression of diabetes have been emerging. In addition, some of anti-diabetic drugs showed robust evidence for reducing the risk of CVD and kidney dysfunction, and American and European guidelines recommend use of these medications independent of A1C in type 2 diabetic patients at risk of developing CVD. This session will provide latest understandings of new emerging concepts for near-normal glycemic control including harm, benefit and therapeutic approach. | ||
|
PR1Diabetes and cardio-renal complications: from epidemiology to precision medicine | |
| Presidential lecture 2 LIVE Channel A | 20:00~20:30 / Thursday 7 October Chairman:Masato Kasuga, Kun-Ho Yoon |
|
|---|---|---|
| Evidence indicating the merits of strict glycemic control especially in early stage of diabetes to decrease the development of microvascular complication and progression of diabetes have been emerging. In addition, some of anti-diabetic drugs showed robust evidence for reducing the risk of CVD and kidney dysfunction, and American and European guidelines recommend use of these medications independent of A1C in type 2 diabetic patients at risk of developing CVD. This session will provide latest understandings of new emerging concepts for near-normal glycemic control including harm, benefit and therapeutic approach. | ||
|
PR2Serotonergic regulation of energy metabolism in peripheral tissues | |
| Presidential lecture 3 LIVE Channel A | 15:30~16:00 / Friday 8 October Chairman:Masato Kasuga, Kun-Ho Yoon |
|
|---|---|---|
| Evidence indicating the merits of strict glycemic control especially in early stage of diabetes to decrease the development of microvascular complication and progression of diabetes have been emerging. In addition, some of anti-diabetic drugs showed robust evidence for reducing the risk of CVD and kidney dysfunction, and American and European guidelines recommend use of these medications independent of A1C in type 2 diabetic patients at risk of developing CVD. This session will provide latest understandings of new emerging concepts for near-normal glycemic control including harm, benefit and therapeutic approach. | ||
|
PR3Analysis of GIP secretion and action by carbohydrate intake | |
| Presidential lecture 4 LIVE Channel A | 19:30~20:00 / Friday 8 October Chairman:Yutaka Seino, Jeong-Taek Woo |
|
|---|---|---|
| Evidence indicating the merits of strict glycemic control especially in early stage of diabetes to decrease the development of microvascular complication and progression of diabetes have been emerging. In addition, some of anti-diabetic drugs showed robust evidence for reducing the risk of CVD and kidney dysfunction, and American and European guidelines recommend use of these medications independent of A1C in type 2 diabetic patients at risk of developing CVD. This session will provide latest understandings of new emerging concepts for near-normal glycemic control including harm, benefit and therapeutic approach. | ||
|
PR42020 The Yutaka Seino distinguished leadership award lecture | |
| Presidential lecture 5 LIVE Channel A | 11:10~11:40 / Saturday 9 October Chairman:Yutaka Seino, Jeong-Taek Woo |
|
|---|---|---|
| Evidence indicating the merits of strict glycemic control especially in early stage of diabetes to decrease the development of microvascular complication and progression of diabetes have been emerging. In addition, some of anti-diabetic drugs showed robust evidence for reducing the risk of CVD and kidney dysfunction, and American and European guidelines recommend use of these medications independent of A1C in type 2 diabetic patients at risk of developing CVD. This session will provide latest understandings of new emerging concepts for near-normal glycemic control including harm, benefit and therapeutic approach. | ||
|
PR5Establishment of a collaborative study network for molecular diabetology in Asia -From insulin Wakayama to AASD- |
|
| Memorial session for Prof. Susumu Seino LIVE Channel A | 20:00~20:30 / Thursday 7 October | |||
|---|---|---|---|---|
| Evidence indicating the merits of strict glycemic control especially in early stage of diabetes to decrease the development of microvascular complication and progression of diabetes have been emerging. In addition, some of anti-diabetic drugs showed robust evidence for reducing the risk of CVD and kidney dysfunction, and American and European guidelines recommend use of these medications independent of A1C in type 2 diabetic patients at risk of developing CVD. This session will provide latest understandings of new emerging concepts for near-normal glycemic control including harm, benefit and therapeutic approach. | ||||
| Moderator: Jun Sung Moon (Yeungnam University, Korea) | ||||
| Condolences |
|
|
||
|
|
|||
| Memorial Lectures |
|
MS1Memorial lecture for Prof. Susumu Seino | ||
|
MS2Memorial lecture for Prof. Susumu Seino | |||
| Commemoration Video |
|
|||
